文献速递药疹与重症皮肤不良反应皮肤肿瘤

白细胞介素-6与肿瘤坏死因子-α同癌症住院患者死亡率的相关性

Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.
PubMed 文献 · J Am Acad Dermatol · 2020-03-12

该回顾性研究纳入144例出现皮疹并接受皮肤科会诊的癌症住院患者,检测血清IL-6、IL-10、TNF-α或elafin。IL-6、IL-10、TNF-α升高与生存期缩短相关,IL-6与TNF-α同时升高者死亡风险近6倍(HR 5.82)。

要点

  • 癌症住院患者皮疹伴IL-6、TNF-α升高提示死亡风险显著增加。
  • IL-6与TNF-α同时升高者死亡风险约为低水平者的6倍(HR 5.82)。
  • 上述细胞因子或可作为该高危人群的预后标志物与治疗靶点。

核心结论

  • 癌症住院患者出现皮疹且IL-6和TNF-α升高时,随访期间死亡可能性近6倍。
  • 这些生物标志物或可作为该高危人群的预后标志物和治疗靶点。

研究设计与样本

  • 回顾性研究,纳入144例出现皮疹、检测血清细胞因子(IL-6、IL-10、TNF-α)或elafin并接受皮肤科会诊的癌症住院患者。
  • 皮疹分为无全身受累的单纯斑丘疹和伴全身受累的复杂斑丘疹。

主要发现

  • IL-6、IL-10、TNF-α升高与生存期缩短相关。
  • IL-6、IL-10、TNF-α升高者总生存率分别为53.7%、56.6%、53.6%,低于低水平者的85.7%、82.5%、83.6%。
  • IL-6与TNF-α同时升高者死亡风险较低水平者增加近6倍(风险比5.82)。

临床怎么用

  • 对癌症住院皮疹患者可检测血清IL-6、IL-10、TNF-α以辅助预后评估。
  • IL-6与TNF-α同时升高者应视为高危人群,加强监测与干预。

局限性

  • 回顾性设计。
  • 样本量有限。
  • 研究人群为高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe cutaneous adverse reactions (SCARs) are associated with high morbidity and mortality in patients with cancer. Early identification and treatment of SCARs may improve outcomes. OBJECTIVE: To identify biomarkers to predict outcomes in hospitalized patients with cancer who developed SCARs. METHODS: Retrospective review of 144 hospitalized patients with cancer with a morbilliform rash, recorded testing for serum cytokines (interleukin [IL]-6, IL-10, and tumor necrosis factor [TNF]-α) or elafin, and a dermatology consultation. Rashes were categorized as simple morbilliform rash without systemic involvement or complex morbilliform rash with systemic involvement. RESULTS: Fifty-four of 144 (37.5%) patients died during follow-up. Elevated levels of IL-6, IL-10, and TNF-α were associated with decreased survival. Overall survivals in patients with elevated levels of IL-6, IL-10, and TNF-α were 53.7%, 56.6%, 53.6%, respectively, compared with 85.7%, 82.5% and 83.6%, respectively, in those with lower levels. Patients with increased levels of both IL-6 and TNF-α had a nearly 6-fold increase in mortality (hazard ratio, 5.82) compared with patients with lower levels. LIMITATIONS: Retrospective design, limited sample size, and high-risk population. CONCLUSIONS: Hospitalized patients with cancer with rash and elevated IL-6 and TNF-α were nearly 6 times more likely to die over the course of follow-up. These biomarkers may serve as prognostic biomarkers and therapeutic targets for this high-risk population.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Stoll JR, Vaidya TS, Mori S, et al. Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer. J Am Acad Dermatol. 2020. PMID: 32171811. doi:10.1016/j.jaad.2020.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。